Further competitor primary biliary cholangitis data from Genfit’s (GNFTF) elafibranor suggest CymaBay Therapeutics’ (CBAY) seladelpar may have a differentiated profile, Cantor Fitzgerald analyst Eliana Merle tells investors in a research note. The analyst keeps an Overweight rating on CymaBay with a $20 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.